A Phase 1 Study of IM-1021 in Participants with Advanced Solid Tumors and Advanced B-cell Lymphomas

The primary objective of this Phase 1 clinical trial is to evaluate the safety and tolerability of IM-1021 in individuals diagnosed with advanced solid tumors or advanced B-cell lymphomas. Determining the safety profile and identifying potential dose-limiting toxicities is essential for establishing the therapeutic window for this investigational agent in oncology.

The study population consists of 76 patients including both male and female participants. The cohort includes individuals categorized within the vulnerable population group. The subjects are diagnosed with advanced solid tumors or advanced B-cell lymphomas. The sponsor did not provide specific information regarding age ranges or lifestyle considerations.

This is a Phase 1 clinical trial evaluating the efficacy and safety of IM-1021 in individuals diagnosed with advanced solid tumors or advanced B-cell lymphomas. The study follows a specific research methodology to assess the investigational product. The sequence of events begins with a screening visit to determine eligibility. Subsequent follow-up visits are scheduled to monitor clinical responses and safety profiles. The process concludes with an end-of-study visit. The total duration of participation is determined by the individual protocol requirements. Early termination from the study may occur based on predefined clinical criteria or safety considerations.

The assessment of efficacy in this study involves evaluating therapeutic responses in patients diagnosed with advanced solid tumors or advanced B-cell lymphomas.